Clinical management of bronchial asthma with inhaled high-dose beclomethasone dipropionate (Beclomet 250--Orion).
The efficacy of inhaled high-dose beclomethasone dipropionate (BDP) in intrinsic and cortico-dependent asthma was studied in 12 asthmatics (3 males and 9 females), average age 39 years (range 17-62 years), with a mean duration of the disease of 9 years (range 2-20 years). The patients were instructed to use one actuation (250 micrograms), three times daily or two actuations three times daily in severe cases in which dyspnoea persisted during the intake of oral corticosteroids. The results during the 6 month follow-up period were: Clinical: dyspnoea, wheeze and cough disappeared or diminished, oral administration of corticosteroids stopped or the daily dose was reduced, the intake of beta-agonists decreased; Functional: after 2-4 weeks, in almost all cases, the base line values of FEV 1.0 and Raw were normal and hyperinflation significantly diminished after the first month of BDP therapy. Clinical and functional improvement were maintained during the follow-up period; no side-effects were revealed.